pirfenidone has been researched along with Bronchiolitis Obliterans in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Brondstetter, T; Chatterjee, P; Cheng, GS; Chiu, W; Hsu, JL; Johnston, L; Matthaiou, EI; Morris, K; O'Donnell, C; Owyang, C; Sharifi, H; Turk, I | 1 |
| Ihle, F; Neurohr, C; von Wulffen, W | 1 |
| Alexander, KA; Antin, JH; Blazar, BR; Cutler, CS; Du, J; Flynn, R; Hill, GR; Koreth, J; Lineburg, KE; Loschi, M; Luznik, L; MacDonald, KP; Maillard, I; Meng, J; Miklos, D; Panoskaltsis-Mortari, A; Paz, K; Ritz, J; Robinson, TM; Roy, S; Schacker, TW; Serody, JS; Vulic, A | 1 |
| Fernandez, F; Jendrisak, M; Margolin, SB; Marshbank, S; McKane, BW; Mohanakumar, T; Narayanan, K | 1 |
| Dosanjh, A | 2 |
| Dosanjh, AK; Morris, RE; Sherwood, S; Throndset, W; Wan, B | 1 |
1 review(s) available for pirfenidone and Bronchiolitis Obliterans
| Article | Year |
|---|---|
Pirfenidone: anti-fibrotic agent with a potential therapeutic role in the management of transplantation patients.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bronchiolitis Obliterans; Humans; Lung Transplantation; Postoperative Complications; Pyridones; Transplantation, Homologous | 2006 |
1 trial(s) available for pirfenidone and Bronchiolitis Obliterans
| Article | Year |
|---|---|
The safety and tolerability of pirfenidone for bronchiolitis obliterans syndrome after hematopoietic cell transplant (STOP-BOS) trial.
Topics: Bronchiolitis Obliterans; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lung; Pyridones | 2022 |
5 other study(ies) available for pirfenidone and Bronchiolitis Obliterans
| Article | Year |
|---|---|
Pirfenidone: a potential therapy for progressive lung allograft dysfunction?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bronchiolitis Obliterans; Cell Proliferation; Disease Progression; Female; Fibrosis; Forced Expiratory Volume; Humans; Lung; Lung Transplantation; Middle Aged; Pyridones; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-β production.
Topics: Allografts; Animals; B-Lymphocytes; Bronchiolitis Obliterans; Chemokine CCL2; Disease Models, Animal; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Interleukin-17; Macrophages; Mice; Mice, Mutant Strains; Pulmonary Fibrosis; Pyridones; Skin Diseases; T-Lymphocytes, Helper-Inducer; Transforming Growth Factor beta | 2017 |
Pirfenidone inhibits obliterative airway disease in a murine heterotopic tracheal transplant model.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bronchiolitis Obliterans; Chronic Disease; Disease Models, Animal; Graft Rejection; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Postoperative Complications; Pyridones; Trachea; Transplantation, Homologous | 2004 |
Pirfenidone and chronic progressive obliterative airway disease.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bronchiolitis Obliterans; Cyclosporine; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Immunosuppressive Agents; Mice; Proteins; Pyridones; Rats | 2006 |
Pirfenidone: a novel antifibrotic agent with implications for the treatment of obliterative bronchiolitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bronchi; Bronchiolitis Obliterans; Cell Division; Cell Survival; Cells, Cultured; Fibroblasts; Flow Cytometry; Humans; Lung; Pyridones | 1998 |